year 16, Issue 6 (November - December 2022)                   Iran J Med Microbiol 2022, 16(6): 520-527 | Back to browse issues page


XML Persian Abstract Print


1- Department of Medical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, Egypt , drrasha_m@mans.edu.eg
2- Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
3- Department of Plastic and Reconstructive Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt
4- Department of Medical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
Abstract:   (1448 Views)

Background and Aim: Pseudomonas aeruginosa (P. aeruginosa) is an important causative organism of burn infection. Several virulence factors are implicated in P. aeruginosa colonization and invasion, making P. aeruginosa infection's outcome worse. Type III secretion system (T3SS) effector proteins are among these virulence factors. The present study evaluated the frequency of genes encoding T3SS effectors as a virulence determinant in P. aeruginosa isolates from burn patients.
Materials and Methods: Wound swabs were collected from burn patients admitted to the Plastic and Reconstructive Surgery Center, Mansoura University, Egypt, and identified by different microbiological testing methods. The modified Kirby Bauer's disc diffusion method was used to test the antibiotic susceptibility of P. aeruginosa isolates against different antibiotics. Prevalence and the presence of exo genes that encode type T3SS proteins (exoS, exoT, exoU, and exoY) in P. aeruginosa isolates were evaluated by the multiplex PCR. Chi-square and Fisher's test were used for statistical analysis.
Results: A total of 45 P. aeruginosa isolates were identified from 101 burn patients, including 27 males and 18 females, with a mean age of 15.78±2.65 years old. P. aeruginosa isolates were mostly susceptible to piperacillin/tazobactam and imipenem (73.33 and 62.22%), respectively; while the lowest susceptibility rates were in ceftazidime (4.44%), Tobramycin (4.44%), and ceftriaxone (6.67%). The exoY and exoT genes were detected in 100% of the P. aeruginosa isolates, while 62.22% and 42.22% of cli­nical isolates harbored exoS and exoU genes, respectively.
Conclusion: This study established a correlation between T3SS proteins, particularly exoS and exoU genes and antimicrobial resistance in P. aeruginosa isolates from burn infection.

Full-Text [PDF 588 kb]   (560 Downloads) |   |   Full-Text (HTML)  (620 Views)  
Type of Study: Original Research Article | Subject: Antibiotic Resistance
Received: 2022/05/16 | Accepted: 2022/08/8 | ePublished: 2022/09/9

References
1. Hasannejad-Bibalan M, Jafari A, Sabati H, Goswami R, Jafaryparvar Z, Sedaghat F, et al. Risk of type III secretion systems in burn patients with Pseudomonas aeruginosa wound infection: A systematic review and meta-analysis. Burns. 2021;47(3):538-44. [DOI:10.1016/j.burns.2020.04.024] [PMID]
2. Quick J, Cumley N, Wearn CM, Niebel M, Constantinidou C, Thomas CM, et al. Seeking the source of Pseudomonas aeruginosa infections in a recently opened hospital: an observational study using whole-genome sequencing. BMJ open. 2014;4(11):e006278. [DOI:10.1136/bmjopen-2014-006278] [PMID] [PMCID]
3. Benie CKD, Dadié A, Guessennd N, N'gbesso-Kouadio NA, Kouame NzD, N'golo DC, et al. Characterization of virulence potential of Pseudomonas aeruginosa isolated from bovine meat, fresh fish, and smoked fish. Eur J Microbiol Immunol. 2017;7(1):55-64. [DOI:10.1556/1886.2016.00039] [PMID] [PMCID]
4. Hassuna NA, Mandour SA, Mohamed ES. Virulence constitution of multi-drug-resistant Pseudomonas aeruginosa in Upper Egypt. Infect Drug Resist. 2020;13:587. [DOI:10.2147/IDR.S233694] [PMID] [PMCID]
5. Emami A, Kazempour A, Pirbonyeh N, Keshavarzi A, Zardosht M. Hospitalization length survey and relation with distribution of LasA protease and type III secretion system encoding-genes in multi-drug resistant Pseudomonas aeruginosa isolates from burn wounds in southwest of Iran. Gene Rep. 2017;9:81-5. [DOI:10.1016/j.genrep.2017.09.006]
6. Khodayary R, Nikokar I, Mobayen MR, Afrasiabi F, Araghian A, Elmi A, et al. High incidence of type III secretion system associated virulence factors (exoenzymes) in Pseudomonas aeruginosa isolated from Iranian burn patients. BMC Res Notes. 2019;12(1):1-6. [DOI:10.1186/s13104-019-4071-0] [PMID] [PMCID]
7. Adwan G. Detection of Type III secretion toxins encoding-genes of Pseudomonas aeruginosa isolates in the West Bank-Palestine. J Adv Biol Biotechnol. 2017;11(3):1-10. [DOI:10.9734/JABB/2017/31319]
8. Gawish AA, Mohamed NA, El-Shennawy GA, Mohamed HA. An investigation of type 3 secretion toxins encoding-genes of Pseudomonas aeruginosa isolates in a University Hospital in Egypt. J Microbiol Infect Dis. 2013;3(03):116-22. [DOI:10.5799/ahinjs.02.2013.03.0093]
9. Kallstrom G. Are quantitative bacterial wound cultures useful? J clin microbiol. 2014;52(8):2753-6. [DOI:10.1128/JCM.00522-14] [PMID] [PMCID]
10. Mahon CR, Lehman DC, Manuselis G. Textbook of diagnostic microbiology-e-book: Elsevier Health Sciences; 2018.
11. Institute CaLS. Performance standards for antimicrobial susceptibility testing: Twenty-seven informational supplements; document (M100-S27): Wayne, PA: CLSI; 2017.
12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-81. [DOI:10.1111/j.1469-0691.2011.03570.x] [PMID]
13. Jarjees KK. Molecular detection of type III secretory toxins in Pseudomonas aeruginosa isolates. Cell Mol Biol. 2020;66(5):9-14. [DOI:10.14715/cmb/2020.66.5.2] [PMID]
14. Ajayi T, Allmond LR, Sawa T, Wiener-Kronish JP. Single-nucleotide-polymorphism mapping of the Pseudomonas aeruginosa type III secretion toxins for development of a diagnostic multiplex PCR system. J Clinical Microbiology. 2003;41(8):3526-31. [DOI:10.1128/JCM.41.8.3526-3531.2003] [PMID] [PMCID]
15. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J infect dis. 2001;183(12):1767-74. [DOI:10.1086/320737] [PMID]
16. Eid D, En W, Barwa R, El-Sokkary MA. Phenotypic and genotypic characterization of some virulence factors in Pseudomonas aeruginosa strains isolated from different clinical sources in Mansoura University Hospitals. New Egypt J Microbiol. 2012;32(2):151-67.
17. Saleh RH, Naher HS, Al-Saadi MAK. Molecular Investigation of Type III Secretion System Toxins-Encoding Genes in Clinical Isolates of Pseudomonas aeruginosa. Med J Babylon. 2012;9(4):857-66.
18. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn Wound Infections. Clin Microbiol Rev. 2006;19(2):403-34. [DOI:10.1128/CMR.19.2.403-434.2006] [PMID] [PMCID]
19. Ghanbarzadeh Corehtash Z, Khorshidi A, Firoozeh F, Akbari H, Mahmoudi Aznaveh A. Biofilm Formation and Virulence Factors Among Pseudomonas aeruginosa Isolated From Burn Patients. Jundishapur J Microbiol. 2015;8(10):e22345. [DOI:10.5812/jjm.22345] [PMID] [PMCID]
20. Shahcheraghi F, Feizabadi MM, Yamin V, Abiri R, Abedian Z. Serovar determination, drug resistance patterns and plasmid profiles of Pseudomonas aeruginosa isolated from burn patients at two hospitals of Tehran (IRAN). Burns. 2003;29(6):547-51. [DOI:10.1016/S0305-4179(03)00142-6]
21. Nikbin VS, Abdi-Ali A, Feizabadi MM, Gharavi S. Pulsed field gel electrophoresis & plasmid profile of Pseudomonas aeruginosa at two hospitals in Tehran, Iran. Indian J Med Res. 2007;126(2):146-52.
22. Horna G, Amaro C, Palacios A, Guerra H, Ruiz J. High frequency of the exoU+/exoS+ genotype associated with multidrug-resistant "high-risk clones" of Pseudomonas aeruginosa clinical isolates from Peruvian hospitals. Sci Rep. 2019;9(1):1-13. [DOI:10.1038/s41598-019-47303-4] [PMID] [PMCID]
23. Finck-Barbançon V, Goranson J, Zhu L, Sawa T, Wiener-Kronish JP, Fleiszig SM, et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol. 1997;25(3):547-57. [DOI:10.1046/j.1365-2958.1997.4891851.x] [PMID]
24. Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology. 2001;147(Pt 10):2659-69. [DOI:10.1099/00221287-147-10-2659] [PMID]
25. Georgescu M, Gheorghe I, Curutiu C, Lazar V, Bleotu C, Chifiriuc M. Virulence and resistance features of Pseudomonas aeruginosa strains isolated from chronic leg ulcers. BMC Infect Dis. 2016;16(1):92. [DOI:10.1186/s12879-016-1396-3] [PMID] [PMCID]
26. Mitov I, Strateva T, Markova B. Prevalence of virulence genes among bulgarian nosocomial and cystic fibrosis isolates of pseudomonas aeruginosa. Braz J Microbiol. 2010;41(3):588-95. [DOI:10.1590/S1517-83822010000300008] [PMID] [PMCID]
27. Fazeli N, Momtaz H. Virulence Gene Profiles of Multidrug-Resistant Pseudomonas aeruginosa Isolated From Iranian Hospital Infections. Iran Red Crescent Med J. 2014;16(10). [DOI:10.5812/ircmj.15722] [PMID] [PMCID]
28. Azimi S, Kafil HS, Baghi HB, Shokrian S, Najaf K, Asgharzadeh M, et al. Presence of exoY, exoS, exoU and exoT genes, antibiotic resistance and biofilm production among Pseudomonas aeruginosa isolates in Northwest Iran. GMS Hyg Infect Control. 2016;11.
29. Park M-H, Kim SY, Roh EY, Lee HS. Difference of Type 3 secretion system (T3SS) effector gene genotypes (exoU and exoS) and its implication to antibiotics resistances in isolates of Pseudomonas aeruginosa from chronic otitis media. Auris Nasus Larynx. 2017;44(3):258-65. [DOI:10.1016/j.anl.2016.07.005] [PMID]
30. Khosravi AD, Shafie F, Montazeri EA, Rostami S. The frequency of genes encoding exotoxin A and exoenzyme S in Pseudomonas aeruginosa strains isolated from burn patients. Burns. 2016;42(5):1116-20. [DOI:10.1016/j.burns.2016.02.012] [PMID]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.